Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for relapse prevention in opioid use disorder
2025-520843-34-00Phase 2Authorised
- Sponsor
- University of Cyprus
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in opioid use disorder (OUD) comparing Adjunctive intravenous ketamine with Adjunctive placebo (2 arms). Primary endpoint: Change in depressive symptom severity. Planned start Apr 2024; status: authorised.
02
Drugs
ketamine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2025-520843-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520843-34-00.